New antibody drugs aim to stop Catheter-Related clots

NCT ID NCT06299111

Completed Prevention Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two experimental drugs, REGN9933 and REGN7508, to see if they can prevent venous thromboembolism (blood clots) in adults who need a PICC line for at least 14 days. The drugs are monoclonal antibodies that target a clotting factor. 195 participants received a single IV dose of one of the drugs or a placebo. Researchers measured how many people developed clots, as well as side effects and bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN9933 and REGN7508 (monoclonal antibodies against factor XI)
What this could lead to: If successful, these drugs could offer a new way to prevent dangerous blood clots in people with central catheters, potentially reducing the need for standard blood thinners.
What could go wrong: This is an early Phase 2 trial with only 195 participants, so results may not apply to everyone. The drugs could cause bleeding or other side effects, and they may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENOUS THROMBOEMBOLISM

Contacts and locations

Locations

Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca

Cluj-Napoca, 400006, Romania
Arensia Research Clinic

Bucharest, 011658, Romania
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Cardiff and Vale University Health Board - University Hospital Wales

Cardiff, Wales, CF14 4XW, United Kingdom
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Hadassah University Medical Center

Jerusalem, 91120, Israel
Henry Ford Health System

Detroit, Michigan, 48202, United States
Juravinski Hospital

Hamilton, Ontario, L8V 1C3, Canada
Lakeridge Health

Oshawa, Ontario, L1G 2B9, Canada
Lanadio Medical Center

Netanya, 4244916, Israel
London Health Sciences Centre

London, Ontario, N6A 4L6, Canada
Memorial Sloan Kettering

New York, New York, 10065, United States
Mount Sinai Medical Center

New York, New York, 10029, United States
Rabin Medical Center

Petah Tikva, 49100, Israel
Shaare Zedek Medical Center

Jerusalem, Jerusalem, 9103102, Israel
Sheba Medical Center

Ramat Gan, 5265601, Israel
Soroka University Medical Center

Beersheba, Southern District, 84101, Israel
Sveta Sofia Hospital

Sofia, 1000, Bulgaria
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Tel Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel
The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, NE1 4LP, United Kingdom
University Health Network

Toronto, Ontario, M5G 2M9, Canada
University hospital Southampton

Southampton, Hampshire, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.